ARA-290

Erythropoietin-derived 11-residue peptide

Identifier graph

Cross-references to canonical chemistry knowledge graphs. Each binding is the same identity used in PubMed-indexed literature.

CAS Registry Number
1208243-50-8 · CAS Common Chemistry
InChIKey
WZTIQQBMSJTRBR-WYKNNRPVSA-N
PubChem CID
CID 91810664
Wikidata
Q27273306
ChEMBL
CHEMBL3545305
Molecular weight
~993 g/mol
IUPAC name
(4S)-5-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-4-amino-1-[[(2S)-1-[[(1S)-1-carboxy-2-hydroxyethyl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-5-oxo-4-[[(2S)-5-oxopyrrolidine-2-carbonyl]amino]pentanoic acid

What is ARA-290?

ARA-290 (Cibinetide) is an 11-residue synthetic peptide derived from the helix-B loop of erythropoietin (EPO). The compound was developed to capture the tissue-protective activity of EPO without its erythropoietic (red-blood-cell- stimulating) effect — the structural region responsible for tissue protection is distinct from the region that engages the classical erythropoietin receptor.

CAS 1208243-50-8, approximate molecular weight 993 Da. Wikidata QID Q27273306, PubChem CID 91810664, ChEMBL ID CHEMBL3545305.

Mechanism of action

ARA-290 binds the innate-repair receptor (IRR) — a heteromer of the classical EPO receptor (EpoR) and the common β receptor (CD131) that mediates tissue-protective effects of EPO without driving erythropoiesis. Activation of this receptor produces anti-inflammatory, anti-apoptotic and tissue-protective signalling in damaged tissue.

Research context

Investigated in clinical and preclinical studies of sarcoidosis-associated small-fibre neuropathy, diabetic neuropathy, and other chronic-inflammatory and neuropathic conditions. ARA-290 has progressed through phase II clinical trials.

Analytical specifications

Every batch of ARA-290 supplied by NMChem is characterised by reversed-phase HPLC for purity determination and by mass spectrometry for identity confirmation. Certificate of Analysis (COA) documents are issued per batch and made available on request.

Identity is confirmed by electrospray-ionisation mass spectrometry (ESI-MS); the observed mass falls within ±2 Da of the theoretical monoisotopic mass calculated from the residue sequence. Purity is determined by reversed-phase HPLC on a C18 column with a trifluoroacetic-acid-modified water/acetonitrile gradient and reported as the area-under-curve percentage of the main peak at 214 nm. NMChem specification is ≥99% main peak. Material ships as lyophilised powder and must be reconstituted in sterile water or bacteriostatic water immediately before use.

Browse the COA database

UK regulatory status

Supplied as a research-grade reference standard for laboratory use only. Not a licensed medicinal product in the United Kingdom and not approved by the MHRA for human or veterinary administration. Sale is restricted to researchers, institutions and laboratory professionals; the compound must be retained within research premises. End-user compliance with the Human Medicines Regulations 2012, the Misuse of Drugs Act 1971 (where applicable) and local institutional biosafety policy is the responsibility of the buyer.

Research literature

Selected peer-reviewed publications from PubMed referencing this compound.

  1. ARA 290 for treatment of small fiber neuropathy in sarcoidosis. van Velzen M et al. · Expert opinion on investigational drugs · 2014
    PubMed PMID 24555851
  2. ARA 290 relieves pathophysiological pain by targeting TRPV1 channel: Integration between immune system and nociception. Zhang W et al. · Peptides · 2016
    PubMed PMID 26774587
  3. Early monocyte modulation by the non-erythropoietic peptide ARA 290 decelerates AD-like pathology progression. Al-Onaizi MA et al. · Brain, behavior, and immunity · 2022
    PubMed PMID 34343617

Related compounds

Other research compounds in adjacent mechanism classes or commonly used alongside ARA-290.

  • BPC-157
    Pentadecapeptide · cytoprotective fragment
  • TB-500
    Synthetic Thymosin Beta-4 fragment · 17-residue peptide

Frequently asked questions about ARA-290

Is ARA-290 the same as Cibinetide?
Yes — Cibinetide is the International Nonproprietary Name (INN) for ARA-290. Both names refer to the same 11-residue EPO-derived peptide.
Why doesn't ARA-290 raise red blood cell count?
ARA-290 was specifically engineered to bind the innate-repair receptor (a heteromer of EpoR and CD131) rather than the classical erythropoietin receptor homodimer (EpoR2) that drives red-cell production. The structural region of EPO responsible for tissue protection is distinct from the region that engages the classical erythropoietic receptor.

Get research-grade ARA-290 from NMChem

UK supplier · HPLC and MS verified · Per-batch Certificate of Analysis · Tracked Royal Mail dispatch.

View product specifications →